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ABSTRACT
Aerosolized prostacyclin (PGI2) has been suggested for selec-
tive pulmonary vasodilation, but its effect rapidly levels off after
termination of nebulization. Stabilization of the second-mes-
senger cAMP by phosphodiesterase (PDE) inhibition may offer
a new strategy for amplification of the vasodilative response to
nebulized PGI2. In perfused rabbit lungs, continuous infusion of
the thromboxane mimetic U46619 was used to establish stable
pulmonary hypertension [increase in pulmonary arterial pres-
sure (pPA) from ;7 to ;32 mm Hg], which is accompanied by
progressive edema formation and severe disturbances in gas
exchange with a predominance of shunt flow (increase from ,2
to ;58%, as assessed by the multiple inert gas elimination
technique). In the absence of PGI2, dose-effect curves for
intravascular and aerosol administration of the specific PDE3
inhibitor motapizone, the PDE4 inhibitor rolipram, and the dual-
selective PDE3/4 inhibitor tolafentrine on pulmonary hemody-
namics were established (potency rank order: rolipram . to-
lafentrine ; motapizone; highest efficacy on coapplication of
rolipram and motapizone). Ten-minute aerosolization of PGI2
was chosen to effect a moderate pPA decrease (;4 mm Hg;
rapidly returning to prenebulization values within 10–15 min)
with only a slight reduction in shunt flow (;49%). Prior appli-
cation of subthreshold doses of i.v. or inhaled PDE3 or PDE4
inhibitors, which per se did not affect pulmonary hemodynam-
ics, caused prolongation of the post-PGI2 decrease in pPA. The
most effective approach, rolipram plus motapizone, amplified
the maximum pPA decrease in response to PGI2 to ;9 to 10
mm Hg, prolonged the post-PGI2 vasorelaxation to .60 min,
reduced the extent of lung edema formation by 50%, and
decreased the shunt flow to ;19% (i.v. rolipram/motapizone)
and 28% (aerosolized rolipram/motapizone). We conclude that
lung PDE3/4 inhibition, achieved by intravascular or transbron-
chial administration of subthreshold doses of specific PDE
inhibitors, synergistically amplifies the pulmonary vasodilatory
response to inhaled PGI2, concomitant with an improvement in
ventilation-perfusion matching and a reduction in lung edema
formation. The combination of nebulized PGI2 and PDE3/4
inhibition may thus offer a new concept for selective pulmonary
vasodilation, with maintenance of gas exchange in respiratory
failure and pulmonary hypertension.
The acute respiratory distress syndrome (ARDS) is char-
acterized by pulmonary hypertension, lung edema formation,
and severe ventilation-perfusion mismatch with a predomi-
nance in shunt flow (Rossaint et al., 1993; Walmath et al.,
1993). Intravascularly administered vasodilators such as
prostacyclin (PGI2) and prostaglandin (PG) E1, used to de-
crease lung (micro-)vascular pressures, are hampered by
their nonselective mode of action, with vasorelaxant proper-
ties in both the pulmonary and systemic vessels and in both
well-ventilated and nonventilated (shunt) areas within the
lung vasculature, thereby disadvantageously increasing
shunt flow (Mélot et al., 1989; Radermacher et al., 1990).
Selective pulmonary vasodilation, in contrast, was first de-
scribed for inhaled nitric oxide (NO) in both acute respiratory
failure and chronic pulmonary hypertension (Frostell et al.,
1991; Pepke-Zaba et al., 1991; Rossaint et al., 1993). Due to
the transbronchial route of application, the vasodilatory
property of this gas-borne agent is restricted to the lung
vasculature. In addition, a regional decrease in pulmonary
vascular resistance in well ventilated lung regions effects
redistribution of blood flow with reduced perfusion of shunt
areas. Considering possible disadvantages of NO because of
its free radical features with impact on inflammatory events
(Troncy et al., 1997), several groups used aerosolization tech-
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nology via the transbronchial route of application for the
vasodilatory prostanoid PGI2, an agent with a well known
pharmacological profile that has been used for many years
(Higgenbottam et al., 1987; Hardy et al., 1988). With this
agent, a decrease in pulmonary arterial pressure (pPA), with
maintenance of systemic arterial pressure, concomitant with
a decrease rather than an increase in shunt flow was dem-
onstrated in patients suffering from severe ARDS (Walmrath
et al., 1993, 1995, 1996; Zwissler et al., 1996). Nebulization of
PGI2 and its longer-acting analog iloprost were also demon-
strated to result in substantial lowering of pPA as well as
resistance and improvement in hemodynamics in nonventi-
lated patients with severe primary and secondary pulmonary
hypertension (Olschewski et al., 1996, 1998a,b). The clinical
use of inhaled PGI2 is, however, hampered by the fact that,
because of the short biological half-life of this agent (2–3 min
at physiological pH; Moncada and Vane, 1980), its vasodila-
tory effect in the lung vasculature levels off within ,30 min
after termination of nebulization (Olschewski et al., 1996).
This window of efficacy is prolonged to '60 to 90 min on
aerosolization of the more stable iloprost. Coapplication of
phosphodiesterase (PDE) inhibitors for stabilization of the
PGI2-induced second-messenger cAMP may offers the possi-
bility of prolonging and possibly increasing the vasodilatory
effect of nebulized PGI2 in the lung vasculature. In vitro
studies in human pulmonary arteries, originating from pa-
tients undergoing surgery for lung cancer, demonstrated the
presence of the PDE isoenzymes 1, 3, 4, and 5 (Rabe et al.,
1994). PDE types 3 and 4 are relevant for cAMP catabolism
in many tissues (Beavo, 1995; Conti et al., 1995; Manganiello
et al., 1995; Torphy, 1998) and were shown to coregulate the
cAMP content in human bronchial smooth muscle cells (Tor-
phy, 1998). PDE5 has little direct impact on cAMP hydrolysis
but is the predominant regulator of the cGMP content,
thereby indirectly influencing cAMP via inhibition of PDE3.
The current study was performed in perfused rabbit lungs
with continuous infusion of the stable thromboxane A2 mi-
metic U46619 for establishing stable pulmonary hyperten-
sion with severe disturbances in gas exchange. Using short-
term aerosolization of PGI2, we investigated the effects of
prior administration of subthreshold doses of selective PDE
inhibitors on the PGI2-elicited vasodilator and gas exchange
response.
Experimental Procedures
Materials. Sterile Krebs-Henseleit hydroxyethylamylopectine
buffer was obtained from Serag-Wiessner (Naila, Germany). The
thromboxane A2 mimetic U46619 was supplied by Paesel-Lorei
(Frankfurt, Germany) and PGI2 (Epostenol) by Wellcome (London,
England). Motapizone was obtained from Nattermann (Köln, Ger-
many), rolipram from Schering A.G. (Berlin, Germany), and the
dual-selective PDE inhibitor tolafentrine from Byk Gulden Pharma-
ceuticals (Konstanz, Germany). All other chemicals were purchased
from Merck (Darmstadt, Germany). The ultrasonic nebulizer Pulmo
Sonic 5500 was obtained from DeVilbiss Medizinische Produkte
GmbH (Langen, Germany).
Isolated-Lung Model. The perfused lung model has been de-
scribed in detail (Seeger et al., 1994). Briefly, rabbits of either sex
weighing 2.6 to 2.9 kg were anticoagulated with heparin (1000 U/kg)
and anesthetized with i.v. ketamine plus xylazine. Tracheostomy
was performed, and the animals were ventilated with room air via a
Harvard respirator (tidal volume, 9–13 ml/kg; frequency, 10 breaths/
min; positive end expiratory pressure, 1 mm Hg). After midsternal
thoracotomy, catheters were placed into the pulmonary artery and
the left atrium, and perfusion with Krebs-Henseleit buffer was
started. The lungs were perfused with a constant flow of 120 ml/min.
Left atrial pressure was set at 1.2 mm Hg in all experiments. In
parallel with the onset of artificial perfusion, room air supplemented
with 4% CO2 was used for ventilation. Lungs were freely suspended
from a force transducer for monitoring of organ weight. Pressures in
the pulmonary artery, left atrium, and trachea were registered (zero
referenced at the hilum). Perfusate samples (total perfusate volume,
500 ml) were taken from both the arterial and venous part of the
system. Gas samples were taken from the outlet of an expiration gas
mixing box. The whole system was heated to 37°C.
Aerosolization. PGI2 and the PDE inhibitors were aerosolized
with an ultrasonic device (Pulmo Sonic 5500). This nebulizer pro-
duces an aerosol with a mass median aerodynamic diameter of 4.5
mm and a geometric S.D. of 2.6, as measured with a laser diffrac-
tometer (HELOS; Sympatec, Clausthal-Zellerfeld, Germany). The
nebulizer was located between the ventilator and the lung to be
passed by the inspiration gas. The nebulization system was de-
scribed previously by Schermuly et al. (1997). For a given ventilator
setting, an absolute deposition fraction of 0.25 6 0.02 was deter-
mined by a laser photometric technique (Schmehl et al., 1996).
Ventilation-Perfusion (V̇A/Q̇) Determination in Isolated
Lungs. The continuous V̇A/Q̇ distributions were determined by the
multiple inert gas elimination technique as described by Wagner et
al. (1974), which has been adapted to assess gas exchange of blood-
free perfused rabbit lungs (Walmrath et al., 1993). Briefly, six inert
gases (sulfur hexafluoride, ethane, cyclopropane, halothane, diethyl
ether, and acetone) were dissolved in isotonic saline and continu-
ously infused at a rate of 0.3 ml/min. After an equilibration period of
at least 30 min, 10-ml perfusate samples were simultaneously col-
lected from the pulmonary artery and the left atrium. A correspond-
ing 30-ml gas sample was drawn from the heated expiration gas
mixing chamber. Each sampling was performed in duplicate. Extrac-
tion of the gases dissolved in the buffer fluid was carried out by
equilibration (40 min) with nitrogen in a shaking water bath (37°C).
The gas phases after equilibration of the buffer samples and the
exhaled gases were analyzed by gas chromatography, as described
(Walmrath et al., 1993). The ratios of arterial to mixed venous
partial pressures (retention) and of expired to mixed venous partial
pressures (excretion) were calculated for each gas and were plotted
against buffer-gas partition coefficients (retention and excretion sol-
ubility curves). For each gas, the retention and the excretion were
used for estimation of the V̇A/Q̇ distribution by least-squares analy-
sis with enforced smoothing with a computer program. The position
of the distribution was also described by the mean V̇A/Q̇ ratio for
perfusion and ventilation and their dispersion by the log S.D. of both
perfusion and ventilation (log S.D. Q̇, log S.D. V̇A). These parameters
of dispersion do not take into account either shunt or dead space. The
residual sum of squares (RSS) was the result of testing the compat-
ibility of the inert-gas data with the derived V̇A/Q̇ distribution by the
least-squares method. An indication of acceptable quality of the V̇A/Q̇
distributions is an RSS of #5.348 in 50% of the experimental runs
(50th percentile) or #10.645 in 90% of the experimental runs (90th
percentile) (Wagner and West, 1984). In this study, 95% of the RSSs
were ,5.348, and 98.8% were ,10.645.
Determination of cAMP in the Recirculating Buffer. Five-
hundred-microliter samples of perfusate were collected at 0, 30, 45,
60, 75, 105, and 135 min and frozen in liquid nitrogen. cAMP was
measured by a radioimmunoassay kit (Immunotech, Marseilles,
France). The perfusate samples or standards were incubated with
125I-labeled cAMP in antibody-coated tubes. After incubation, the
contents of the tube were aspirated, and bound radioactivity was
counted in a gamma counter. Duplicate samples were performed,
and the values were calculated by a standard curve. The cAMP levels
are given as picomoles per milliliter.
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Experimental Protocols. As described previously (Walmrath et
al., 1997), a sustained increase in pPA from '6 to '32 mm Hg was
achieved by continuous infusion of 70 to 160 pmol z kg21 z min21 of
U46619; individual titration was performed. This level of pulmonary
hypertension was then maintained for at least 150 min, with varia-
tions in pPA of ,2 mm Hg. In pilot studies, aerosolized PGI2 was
applied via inhalation in increasing doses, and a dose of 27 pmol z
kg21 z min21 was found to decrease pPA by ;4.0 mm Hg when
administered over a 10-min aerosolization period. The efficacy of the
PDE inhibitors was assessed in dose-response curves for rolipram,
motapizone, and tolafentrine; these agents were either bolus injected
into the recirculating buffer fluid or nebulized over a 10-min period.
In separate experiments, a subthreshold dose of the PDE inhibitor,
with no effect on pPA and gas exchange per se, was administered
either i.v. or via the inhalative route, followed by subsequent PGI2
inhalation. The following experimental groups were used:
● Control lungs (n 5 6): After termination of the steady-state
period, V̇A/Q̇ measurements were performed at 30, 45, 60, 75,
105, and 135 min; no interventions were undertaken.
● U46619 lungs (n 5 6): After termination of the steady-state
period, U46619 was continuously infused for 135 min to provoke
an increase in pPA to ;32 mm Hg. V̇A/Q̇ measurements were
performed 30, 45, 60, 75, 105, and 135 min after the beginning
of the U46619 application.
● Dose-response curve of inhaled and infused PDE inhibitors (n 5
4 each): U46619 was correspondingly infused, and after estab-
lishment of stable pulmonary hypertension, increasing doses of
the PDE inhibitors were either bolus injected into the recircu-
lating buffer or nebulized. The doses were 10, 50, 100, 1,000,
and 10,000 nM and 0.17, 1.72, and 6.7 nmol z kg21 z min21 for i.v.
and nebulized rolipram, respectively; 10, 100, 1,000, 10,000, and
100,000 nM and 0.7 and 6.5 nmol z kg21 z min21 for motapizone;
and 0.02, 0.2, 1, 2, 20, 100, and 200 mM and 1.2, 12, and 120
nmol z kg21 z min21 for tolafentrine. Furthermore, the combina-
tion of motapizone and rolipram was tested with the following
concentrations, which were either applied i.v. (1, 10, and 100 nM
motapizone; 1, 5, and 50 nM rolipram) or nebulized (0.13, 0.65,
and 6.5 nmol z kg21 z min21 motapizone and 0.13, 0.67, and 6.7
nmol z kg21 z min21 rolipram).
● PGI2 inhalation (n 5 6): U46619 was administered as described.
Forty-five minutes after onset of U46619 infusion, PGI2 was
aerosolized for 10 min at a dose of 27 pmol z kg21 z min21. V̇A/Q̇
measurements were carried out after 30, 45, 60, 75, 105, and
135 min.
● PGI2 inhalation combined with i.v./inhaled PDE inhibitors (n 5
6 each): U46619 was infused in a corresponding fashion, and
after 30 min, a subthreshold concentration of one of the PDE
inhibitors was either infused or nebulized. The dosage was
taken from the dose-response curve established in the preceding
experiments. The doses used in these experiments were (for
infusion and nebulization, respectively) 50 nM and 0.9 nmol z
kg21 z min21 rolipram, 100 nM and 6.5 nmol z kg21 z min21
motapizone, 65 nM and 1.2 nmol z kg21 z min21 tolafentrine, and
1/1 nM and 135/131 pmol z kg21 z min21 (infusion/inhalation) for
the combination of rolipram and motapizone. Fifteen minutes
after subthreshold PDE administration, PGI2 nebulization was
performed as described for the PGI2 group (27 pmol z kg
21 z
min21). V̇A/Q̇ distributions were determined at the same time
points as detailed for the preceding experiments.
Data Analysis. All values are given as means 6 S.E. or as
coefficient of variation (S.D./mean, %). For analysis of statistical
difference, two-tailed Student’s t test for unpaired samples was per-
formed. After Bonferroni’s correction, P , .05 was considered signif-
icant.
Results
Baseline Conditions. After termination of the steady-
state period, all lungs displayed pPA values between 5 and 7
mm Hg. Baseline V̇A/Q̇ measurements revealed unimodal
narrow distribution of perfusion and ventilation to midrange
V̇A/Q̇ (0.1 , V̇A/Q̇ , 10) areas throughout (Table 1). Shunt
flow (V̇A/Q̇ , 0.005) and perfusion flow to poorly ventilated
areas (0.005 , V̇A/Q̇ , 0.1) were extremely low (,2.5%), and
no perfusion to high V̇A/Q̇ regions (10 , V̇A/Q̇ , 100) was
observed (not shown in detail). Dead space (V̇A/Q̇ . 100)
approximated 50% of ventilation in system isolated-lung ven-
tilation this.
U46619-Elicited Pulmonary Hypertension and Gas
Exchange Abnormalities. Continuous infusion of 130 6 27
pmol z kg21 z min21 (all experiments) of U46619 provoked an
increase in pPA to 32.5 6 1.1 mm Hg within 25 min, with
subsequent plateauing of pulmonary hypertension. The pPA
rise was accompanied by a delayed-onset lung weight gain
and a progressive increase in shunt flow to 58.1 6 3.6% of
total lung perfusion after 135 min (Table 1 and Fig. 1). Dead
space increased by ;10% (data not shown). A marked broad-
ening of flow dispersion and ventilation distribution in the
midrange V̇A/Q̇ regions was noted under these conditions.
The lung weight progressively increased resulting in a total
weight gain of 16.6 6 1.7 g at the end of the experiments (Fig.
2).
Dose-Response Curves of PDE Inhibitors. As shown in
Fig. 3, all intravascularly administered PDE inhibitors ef-
fected a dose-dependent reduction in elevated pPA values in
lungs with U46619-elicited pulmonary hypertension. Rolip-
ram showed the highest efficacy (dose range, 10–10,000 nM),
followed by tolafentrine (range, 0.02–200 mM) and motapi-
zone (range, 0.01–100 mM). Combination of subthreshold
doses of motapizone (100 nM) and rolipram (50 nM) resulted
in a marked amplification of vasodilatory efficacy (Fig. 4).
Even a 10-fold-lower dose of each agent reduced the elevated
pressure by 9.2 6 1.7% on coapplication. Inhalation of rolip-
ram and motapizone was virtually ineffective up to a dose of
6.7 nmol z kg21 z min21 for each agent (Fig. 4). When com-
bined, amplification of the pulmonary vasodilatory effect was
again obvious, demonstrated even for 10-fold-lower doses of
each PDE inhibitor (Fig. 4). Tolafentrine decreased the ele-
vated pPA values in response to U46619 infusion by 23.8 6
3.3% at the very high dose of 120 nmol z kg21 z min21 (data
not shown in detail).
Nebulization of PGI2. Inhalation of aerosolized PGI2 at a
dose of 27 pmol z kg21 z min21 for 10 min resulted in a
significant reduction in U46619-induced pulmonary hyper-
tension, with pPA values decreasing by a mean of 4 mm Hg
(Fig. 5). The vasodilatory effect commenced within 2 min
after onset of nebulization. Immediately after stopping the
aerosol application, pPA started to rise again, and prenebu-
lization values were reached within 15 min. The development
of intrapulmonary shunt flow was moderately lowered in
response to PGI2 aerosolization but did not differ signifi-
cantly from the U46619 group (maximum 48.7 6 5.3% at the
end of the experiments; Fig. 1). Broadening of flow dispersion
and ventilation distribution in the midrange V̇A/Q̇ regions
was comparable to that in the U46619 group. The total
weight gain of the lungs was 17.3 6 2.9 g at the end of the
experiments (Fig. 2).
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Combined Subthreshold Administration of PDE In-
hibitors and PGI2 Nebulization. The doses of the different
PDE inhibitors in these studies were derived from the dose-
inhibition curves, targeting a subthreshold dosage with no
effect of the mode of PDE inhibition on the pulmonary vas-
cular tone per se. All subthreshold interventions for PDE
inhibition did, however, clearly affect responsiveness to the
subsequent standardized PGI2 nebulization.
Rolipram. In the presence of i.v. or inhaled rolipram, the
PGI2-induced maximum pPA decrease was not augmented,
but the pPA values did not fully return to the preceding
U46619-elicited plateau within the subsequent 100-min ob-
servation period (Figs. 5 and 6). The increase in weight gain
was significantly decreased by both routes of rolipram appli-
cation (Fig. 2). There was some reduction in shunt flow in the
i.v. rolipram/PGI2 and the aerosol rolipram/PGI2 lungs, but
the difference to the lungs with PGI2 nebulization alone was
not significant (Table 1). This was also true for the broaden-
ing of the perfusion dispersion and ventilation distribution in
the midrange V̇A/Q̇ areas.
Motapizone. Subthreshold doses of inhaled motapizone,
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 1. Influence of PGI2 nebulization and its combination with sub-
threshold doses of PDE inhibitors on U46619-induced intrapulmonary
shunt flow. The timing of the interventions is indicated. Means 6 S.E. of
six independent experiments are given. Shunt, percentage of perfusion on
nonventilated areas (V̇A/Q̇ , 0.005); Roli/Mota aer., aerosolization of 135
pmol z kg21 z min21 of rolipram and 131 pmol z kg21 z min21 of motapizone
for 10 min before PGI2 nebulization; Roli/Mota i.v., intravascular appli-
cation of rolipram (1 nM) and motapizone (1 nM) before PGI2 nebuliza-
tion; * P , .05, ** P , .01, *** P , .001, compared with lungs with PGI2
inhalation alone.
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pPA decrease in response to the subsequent PGI2 nebuliza-
tion from '4 to '8 mm Hg. Both routes of motapizone ad-
ministration moderately retarded the pPA return to pre-PGI2
values. No significant changes in intrapulmonary shunt flow,
gas exchange variables, or weight gain were noted in the
lungs undergoing either intravascular or transbronchial mo-
tapizone application before PGI2 nebulization, compared
with the lungs with PGI2 aerosolization alone.
Tolafentrine. Intravenous administration of the dual-se-
lective PDE3/4 inhibitor tolafentrine significantly amplified
(DpPA '8 instead of 4 mm Hg) and prolonged (.90 versus 15
min) the vasodilatory efficacy of PGI2 nebulization (Fig. 7).
When applied via inhalation, the same trend of tolafentrine
efficacy was noted but was much less obvious. Neither mode
of tolafentrine administration significantly influenced lung
weight gain and gas exchange variables.
Combined Rolipram and Motapizone. Intravenous
preapplication of subthreshold doses of rolipram plus motapi-
zone markedly amplified the PGI2-elicited pPA decrease
('10 compared with '4 mm Hg for PGI2 alone) (Fig. 5).
Moreover, the post-PGI2 vasorelaxation was prolonged to
.60 min, compared with '10 to 15 min. Nearly the same
profile was noted for preapplication of subthreshold doses of
rolipram/motapizone via inhalation. In addition, both ap-
proaches reduced lung edema formation by '50% (Fig. 2). As
shown in Fig. 1, intrapulmonary shunt flow was significantly
decreased (maximum shunt, '19 and '28% in lungs pre-
treated with rolipram/motapizone via intravascular and in-
trabronchial routes, respectively, compared with '49% with
PGI2 alone). Most of this shunt reduction occurred in favor of
higher percentages of flow being distributed to normal V̇A/Q̇
regions, but an increase in perfusion of low V̇A/Q̇ areas was
also noted (Table 1). The broadening of flow dispersion and
ventilation distribution in the midrange V̇A/Q̇ regions was
not significantly affected (Table 1).
Ventilation Pressures. Peak airway pressure during
constant-volume ventilation did not significantly change in
any of the experimental groups (data not given in detail).
Measurement of cAMP. The impact of aerosolized mo-
tapizone, aerosolized rolipram, and a combination of these
PDE inhibitors on PGI2-elicited cAMP liberation was inves-
tigated (Fig. 8). In control experiments with U46619 infusion,
perfusate cAMP concentrations slowly increased to 4 to 5
pmol/ml. Inhalation of PGI2 resulted in an increase in cAMP
to maximum values of '9 pmol/ml. A further increase in
cAMP was noted on coadministration of the PDE3 inhibitor
motapizone and the PDE4 inhibitor rolipram (maximum per-
fusate levels, '13–14 pmol/ml). The most prominent eleva-
tion of perfusate cAMP levels occurred on combination of
motapizone and rolipram with PGI2 (maximum cAMP levels,
'16 pmol/ml). These data match the efficacy of these agents
and combinations in reducing U46619-elicited pulmonary hy-
pertension.
Discussion
Continuous infusion of the thromboxane A2 mimetic
U46619 has repeatedly been used to establish stable pulmo-
nary hypertension in perfused rabbit lungs, suitable for test-
Fig. 2. Lung weight gain in response to U46619 infusion in the different
experimental groups. Means 6 S.E. of six independent experiments are
given. Roli, rolipram; Mota, motapizone; Tola, tolafentrine. * P , .05,
** P , .01, compared with lungs with PGI2 inhalation alone. Control
lungs received neither U46619 nor vasodilatory agent.
Fig. 3. Dose-effect curves of intravascular PDE inhibitors on U46619-
elicited pulmonary hypertension. The decrease in pPA in response to each
PDE dose (concentrations related to the recirculating perfusate) is given
(mean 6 S.E.). ** P , .01; *** P , .001, compared with lungs with
U46619-elicited pulmonary hypertension.
Fig. 4. Influence of fixed doses of intravascular and inhaled PDE inhib-
itors and combinations of these agents on U46619-elicited pulmonary
hypertension. The decrease in pPA in response to each intravascular PDE
dose or combination (concentrations related to the recirculating perfus-
ate) or nebulized PDE dose or combination (10-min aerosolization peri-
ods) is given (in percentage of the U46619-elicited pPA increase). Mean 6
S.E. of six independent experiments. Roli, rolipram; Mota, motapizone;
Tola, tolafentrine. * P , .05, ** P , .01, compared with U46619 lungs.
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ing the effects of pharmacological agents on pulmonary he-
modynamics (Rimar and Gillis, 1993, 1995; Lindeborg et al.,
1995; Walmrath et al., 1997). Similar to inhaled NO, aero-
solized PGI2 was previously shown to be an effective pulmo-
nary vasodilator in this model, with substantial reduction in
precapillary and moderate relief of postcapillary vascular
resistance (Walmrath et al., 1997). When investigated in the
absence of PGI2, both intravascular and aerosol delivery of
the PDE3 and PDE4 inhibitors motapizone and rolipram
caused dose-dependent pulmonary vasodilation in the lungs
with U46619-elicited hypertension. When calculated on a
molar basis, higher efficacy and potency of rolipram over
motapizone was observed for both routes of application. Pro-
nounced synergism was obvious when combining PDE3 and
PDE4 inhibition, again for both routes of drug delivery: co-
application of 1/10 of the subthreshold dose of each substance
sufficed to cause a significant decrease in pPA not antici-
pated from the dose-response curves of either motapizone or
rolipram. This is in line with studies in PGF2a-constricted
human pulmonary artery rings, in which the combination of
motapizone and rolipram was found to be effective in induc-
ing relaxation (Rabe et al., 1994), and with results from
intact rabbits with pulmonary hypertension, also demon-
strating high vasodilatory efficacy of i.v. coapplication of
motapizone and rolipram (D.W., R.T.S., and W.S., in prepa-
ration). In smooth muscle cells originating from human air-
ways, the cAMP content was essentially regulated by the
activities of PDE3/4 pathways, and a corresponding profile
may hold true for pulmonary vascular smooth muscle cells
(Pan et al., 1994; Torphy, 1998). Inhibition of either PDE3 or
PDE4 might partly be compensated for by enhanced break-
down of cAMP through the alternate catabolic pathway,
whereas dual inhibition of both PDE3 and PDE4 is fully
effective in elevating cAMP levels. Correspondingly, the du-
Fig. 5. Influence of PGI2 nebulization
with and without prior intravascular
administration of subthreshold doses
of selective PDE inhibitors on U46619-
elicited pulmonary hypertension. The
timing of interventions is indicated;
the following doses were used: 50 nM
rolipram, 100 nM motapizone, and 1
nM/1 nM for the combination of rolip-
ram and motapizone. Means 6 S.E. of
six independent experiments are given.
Roli, rolipram; Mota, motapizone. * P ,
.05; ** P , .01, compared with lungs
with PGI2 inhalation alone.
Fig. 6. Influence of PGI2 nebulization
with and without prior aerosol admin-
istration of subthreshold doses of selec-
tive PDE inhibitors on U46619-elicited
pulmonary hypertension. The timing
of interventions is indicated; the fol-
lowing doses were used: 0.9 nmol z
kg21 z min21 rolipram, 6.5 nmol z kg21 z
min21 motapizone, and 135 pmol z
kg21 z min21 rolipram plus 131 pmol z
kg21 z min21 motapizone. Means 6
S.E. of six independent experiments
are given. Roli, rolipram; Mota, mo-
tapizone. * P , .05 compared with
lungs with PGI2 inhalation alone.
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al-selective PDE3/4 inhibitor tolafentrine exerted strong pul-
monary vasodilation in the U46619-constricted pulmonary
vasculature; however, when calculated on a molar basis, this
agent was less efficient than the combination of motapizone
and rolipram by .2 orders of magnitude.
Most interesting, a marked synergistic amplification of the
pulmonary vasodilatory effect of nebulized PGI2 was noted
when this approach was combined with preapplication of
subthreshold doses of the PDE inhibitors, which per se
caused no hemodynamic effects. The pPA decrease in re-
sponse to the PGI2 aerosol, leveling off within 10 to 15 min
after termination of nebulization because of the short half-
life of this prostanoid (Moncada and Vane, 1980), was pro-
longed in the presence of subthreshold doses of all PDE
inhibitors investigated. This was most prominent for the
combination of motapizone and rolipram, whether admixed
to the perfusion fluid or administered via the inhalative route
in a preceding aerosolization maneuver: the maximum pPA
decrease in response to PGI2 nebulization more than dou-
bled, and sustained pulmonary vasodilation for .60 min was
noted. Similar efficacy was noted for subthreshold doses of
the dual-selective inhibitor tolafentrine when administered
intravascularly, with somewhat lower efficacy of this agent
via inhalation. These data correspond with previous studies
in isolated pulmonary artery rings from rats with hypoxia-
induced pulmonary hypertension, in which an enhancement
of isoproterenol and forskolin-induced relaxation was noted
in the presence of PDE3 and PDE4 inhibitors (Wagner et al.,
1997). Again, stabilization of PGI2-induced cAMP resulting
from inhibition of both PDE pathways offers the most prob-
able explanation for the high efficacy of combined PDE3/4
inhibition. This view is well supported by the current mea-
surements of perfusate cAMP levels, being highest on coap-
plication of PDE3 and PDE4 inhibitors with PGI2.
For a detailed analysis of gas exchange, the multiple inert
gas elimination technique was used, the feasibility and va-
lidity of which has been documented in isolated, blood-free
perfused rabbit lungs (Walmrath et al., 1997). Under base-
line conditions, physiological V̇A/Q̇ matching was noted. In
Fig. 7. Influence of PGI2 nebulization
with and without prior intravascular or
aerosol administration of subthreshold
doses of tolafentrine on U46619-elicited
pulmonary hypertension. The timing of
interventions is indicated; the following
doses were used: 65 nM of i.v. tolafen-
trine and 1.2 nmol z kg21 z min21 of aero-
solized tolafentrine. Means 6 S.E. of six
independent experiments are given. Tola,
tolafentrine. * P , .05 compared with
lungs with PGI2 inhalation alone.
Fig. 8. Influence of PGI2 nebulization with and without prior aerosol
administration of subthreshold doses of PDE inhibitors on cAMP levels in
lung perfusate. The timing of interventions is indicated; the following
doses were used: 0.9 nmol z kg21 z min21 of rolipram, 6.5 nmol z kg21 z
min21 of motapizone, 135 pmol z kg21 z min21 of rolipram plus 131 pmol z
kg21 z min21 of motapizone. Means 6 S.E. of six independent experiments
are given. Roli, rolipram; Mota, motapizone. * P , .05 compared with
lungs with PGI2 inhalation alone.
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sharp contrast, the U46619-elicited pulmonary hypertension
was accompanied by gas exchange abnormalities, of which
the predominant abnormality was a dramatic increase in
shunt flow to .50%. Such a marked shunt flow might be
largely attributable to the progressive formation of lung
edema in response to ongoing U46619 infusion; however,
several observations challenge such a simple view. First, the
total amount of edema formation was still moderate (10–15 g
when shunt already approached 50% compared with .50 g
under conditions of frank alveolar edema filling of the rabbit
lungs). Second, shunt flow commenced before onset of signif-
icant lung weight gain, and it is known to be partly reversible
on offset of U46619 infusion despite further progression of
edema formation (Walmrath et al., 1997). Third, all “thera-
peutic” rolipram groups displayed an ;50% decrease in
edema formation in this study. However, only the simulta-
neous application of rolipram and motapizone reduced the
shunt flow to substantially lower values, with no difference
in lung weight gain between the rolipram-alone and the
rolipram plus motapizone groups (see below). Thus, as pre-
viously suggested (Walmrath et al., 1997), the coappearance
of edema formation and marked pPA elevation in response to
the vasoconstrictor agent U46619 is suggested as the pre-
dominant mechanism underlying the excessive shunt flow.
Pressure-driven redistribution of perfusion to edema-filled
regions or otherwise nonventilated areas must be assumed
and is spared from perfusion by hypoxic vasoconstriction at
normal pPA. An alternative explanation would be recruit-
ment of very short term constant pathways or pathways
shunting exchange areas, assumed to contribute to lung per-
fusion under conditions of pulmonary hypertension.
The gas exchange abnormalities with high shunt flow in
this model of acute pulmonary hypertension are similar to
those encountered under clinical conditions of ARDS. Inhaled
PGI2 has been shown to decrease pulmonary hypertension in
patients with ARDS without affecting systemic pressure
(Walmrath et al., 1993). Interestingly, transbronchial and
intravascular coapplication of PDE inhibitors to enhance the
vasodilatory effect of PGI2 was not accompanied by a deteri-
oration in gas exchange, as repeatedly demonstrated for i.v.
use of vasodilators in diseased lungs (Mélot et al., 1989;
Radermacher et al., 1990). In contrast, V̇A/Q̇ matching im-
proved, again most obviously for rolipram plus motapizone.
In the presence of this combination of PDE3/4 inhibitors, the
shunt flow was reduced by '50% compared with the PGI2-
only group. This impact on V̇A/Q̇ matching translates into a
marked improvement in arterial oxygenation when occurring
in vivo.
Two underlying mechanisms may explain the impressive
beneficial effect of rolipram plus motapizone on the U46619-
elicited gas exchange abnormalities. First, a reduction in
lung edema formation was obvious for all lungs receiving
rolipram plus aerosolized PGI2 and was not reproduced by
motapizone or tolafentrine. In addition to its effect via reduc-
ing the capillary filtration pressure, some direct effect of
rolipram on microvascular permeability may be operative, as
suggested from in vitro studies (Suttorp et al., 1993; Barnard
et al., 1994; Miotla et al., 1998). However, the impact of
rolipram on lung fluid balance may well contribute to, but
may not solely explain, the improvement in gas exchange in
the lungs with rolipram plus motapizone, because the total
weight gain in this group did not significantly differ from the
rolipram-only group. Second, V̇A/Q̇ is improved. Via stabili-
zation of the second-messenger cAMP, subthreshold doses of
rolipram plus motapizone, causing no hemodynamic effects
per se, may amplify PGI2-induced pulmonary vasodilation,
whereas this effect is still restricted to the aerosol-accessible
(i.e., well ventilated) lung areas with redistribution of blood
flow from the nonventilated (shunt) regions. Notably, this
profile of enhanced pulmonary vasorelaxation and improve-
ment in gas exchange was true for both aerosol and intra-
vascular administration of subthreshold doses of rolipram
plus motapizone. Moreover, the use of subthreshold doses in
this study is of interest, because under clinical conditions,
higher dosages of PDE3 inhibitors are hampered by several
cardiovascular side effects, including life-threatening arryth-
mias in patients with compromised cardiac function (Nac-
carelli and Goldstein, 1989), which may limit the use of these
agents in patients with pulmonary hypertension. PDE4 in-
hibitors, especially rolipram, may induce emesis, gastric se-
cretion, and psychotropic effects in the normal dose range (for
overview, see Torphy, 1998).
In conclusion, our study demonstrates that the pulmonary
vasodilatory effect of nebulized PGI2 may be significantly
enhanced and prolonged by coapplication of subthreshold
doses of PDE3 and PDE4 inhibitors, which exert no hemody-
namic effects per se. Both the intravascular and the trans-
bronchial routes of PDE inhibitor administration may be
used for this purpose. Note that, in contrast to the common
finding of deterioration of gas exchange when using i.v. va-
sodilators in diseased lungs, shunt flow did not increase.
However, the most effective approach for PDE3/4 inhibition
even significantly decreased the perfusion of shunt areas and
redistributed flow to well ventilated lung regions. The profile
of nebulized PGI2—relief of pulmonary hypertension and
improvement of gas exchange due to targeting the vasorelax-
ant properties to well ventilated regions of the lung—is thus
further intensified by combination with suitable subthresh-
old PDE inhibition for prolonged half-life of the second-mes-
senger cAMP.
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